Session Details
[O2]Cancer Genetics 1 (English Session)
Thu. Nov 19, 2026 10:10 AM - 11:10 AM JST
Thu. Nov 19, 2026 1:10 AM - 2:10 AM UTC
Thu. Nov 19, 2026 1:10 AM - 2:10 AM UTC
Room 6 (Meeting Room 3, Exhibition Building, Sendai International Center)
Chair: Akira Hirasawa (Department of Clinical Genomic Medicine, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama, Japan), Yukihide Momozawa (RIKEN)
［English Session］
[O2-01]Characterization of URST1 as a new prognostic biomarker and therapeutic target for lung cancer
Atsushi Takano1,2,3, Yohei Miyagi4, Yataro Daigo1,2,3 (1. Platform Office, Institute of Medical Science, The University of Tokyo, Tokyo, Japan, 2. Department of Medical Oncology and Cancer Center, Shiga University of Medical Science, 3. Center for Advanced Medicine against Cancer, Shiga University of Medical Science, 4. Molecular Pathology and Genetics Division, Kanagawa Cancer Center)
[O2-02]Structure-Based Identification and Functional Validation of Cancer Driver Gene Candidates
Miku Soeda, Akihiro Fujimoto, Motoko Unoki, Ko Ikemoto, Ryoji Kuribayashi (Department of Human Genetics, School of International Health, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan)
[O2-03]Alternative splicing rewires therapeutic response to RAS/MAPK pathway inhibitors in lung cancer
Taiki Abe1,2,3, Taylor Won4,5, Colette Felton4,5, Kevin Levine1, Alice Berger1, Angela Brooks4,5 (1. Human Biology Division, Fred Hutchinson Cancer Center, 2. Tohoku University School of Medicine, 3. School of Pharmaceutical Sciences, University of Shizuoka, 4. Department of Biomolecular Engineering, University of California, 5. UC Santa Cruz Genomics Institute, University of California)
[O2-04]Multi-omic analysis of Multiple Endocrine Neoplasia Type 1 with spatial transcriptomics
Akane Naruoka1, Keiichi Ohshima1, Takashi Sugino2, Kouji Muramatsu2, Takeshi Nagashima3,4, Masakuni Serizawa1, Keiichi Hatakeyama5, Ohnami Sumiko3, Shunpei Ohnami3, Kouji Maruyama6, Yasue Horiuchi3, Yuji Shimoda3, Akira Iiduka7, Katsumasa Miyake8, Kenichi Urakami3, Yasuto Akiyama7, Ken Yamaguchi9 (1. Drug discovery and development division, Shizuoka Cancer Center Research Institute, 2. Division of Pathology, Shizuoka Cancer Center Hospital, 3. Cancer Diagnostics Research Division, Shizuoka Cancer Center Research Institute, 4. SRL Inc., 5. Cancer Multiomics Div. Shizuoka Cancer Ctr. Res. Inst., 6. Experimental Animal Facility Div. Shizuoka Cancer Ctr. Res. Inst., 7. Immunotherapy Div. Shizuoka Cancer Ctr. Res. Ins., 8. Med. Genetics Div. Shizuoka Cancer Ctr. Res. Inst., 9. Shizuoka Cancer Center)
[O2-05]Identification of URST4 as a promising candidate biomarker and therapeutictarget for breast cancer.
Hoa Thi Nguyen1, Yataro Daigo1,2, Atsushi Takano1,2, Yohei Miyagi3 (1. Department of Medical Oncology and Cancer Center; Center for Advanced Medicine against Cancer, Shiga University of Medical Science, Japan, 2. Center for Antibody and Vaccine Therapy, Research Hospital, Institute of MedicalScience, The University of Tokyo, Japan, 3. Molecular Pathology and Genetics Division, Kanagawa Cancer Center, Japan)
[O2-06]Deep learning reinterpretation of germline VUS in hereditary cancer syndromes
Mario Bernabeu Aracil1, Ana Fernandez Montes2, Jesus Garcia Mata2, María del Carmen Penín Corderi2, Silvia Carles Gonzalez1, Jimena Massiel Flores Ñaupari1, Nooshin Bayat3, Laura Martinez Gomez3, Kristina Ibañez3, Ander Martinez3, Nuria Garcia Santa3, Abe Shuya4, Sho Takishita4, Fuji Masaru4, Clara Ruiz Ponte1, Serban Georgescu5, Raul Valin3, Ceres Fernandez Rozadilla1 (1. Health Research Institute of Santiago de Compostela (IDIS), Spain, 2. Complexo Hospitalario Universitario de Ourense, Spain, 3. Fujitsu Research of Europe Sucursal en España, Spain, 4. Fujitsu Research, Fujitsu Ltd, Japan, 5. Fujitsu Research of Europe, United Kingdom)